A cationic nanoemulsion for the delivery of next-generation RNA vaccines

Molecular Therapy

Volumn 22, Issue 12, 2014, Pages 2118-2129

  Brito, Luis A ^a   Chan, Michelle ^a   Shaw, Christine A ^a   Hekele, Armin ^a   Carsillo, Thomas ^a   Schaefer, Mary ^a   Archer, Jacob ^a   Seubert, Anja ^b   Otten, Gillis R ^a   Beard, Clayton W ^a   Dey, Antu K ^a   Lilja, Anders ^a,c   Valiante, Nicholas M ^a   Mason, Peter W ^a   Mandl, Christian W ^a   Barnett, Susan W ^a   Dormitzer, Philip R ^a   Ulmer, Jeffrey B ^a   Singh, Manmohan ^a   O'Hagan, Derek T ^a   Geall, Andrew J ^a   more..

^a Novartis Vaccine   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c Helmut Qualtinger Gasse 2   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; FUSION GLYCOPROTEIN; GLYCOPROTEIN B; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; MESSENGER RNA; NEUTRALIZING ANTIBODY; PHOSPHOPROTEIN 65 IMMEDIATE EARLY PROTEIN 1 FUSION PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RNA VACCINE; SELF AMPLIFYING MESSENGER RNA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; CATION; DNA VACCINE; EMULSION; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOGENICITY; MOUSE; NANOEMULSION; NEUTROPHIL CHEMOTAXIS; NEW ZEALAND WHITE (RABBIT); NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN EXPRESSION; RAT; RHESUS MONKEY; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; EMULSION; FEMALE; IMMUNOLOGY; PROCEDURES; RABBIT;

ANIMALIA; MUS; ORYCTOLAGUS CUNICULUS; PRIMATES; RATTUS;

ANIMALS; CATIONS; DRUG DELIVERY SYSTEMS; EMULSIONS; FEMALE; IMMUNITY, CELLULAR; MACACA MULATTA; MICE; MICE, INBRED BALB C; RABBITS; RATS; RNA, MESSENGER; RNA, VIRAL; VACCINES, DNA;

EID: 84927176976     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.133     Document Type: Article

References (46)

1. Rappuoli, R, Mandl, CW, Black, S and De Gregorio, E (2011). Vaccines for the twentyfirst century society. Nat Rev Immunol 11: 865-872.
2. Kutzler, MA and Weiner, DB (2008). DNA vaccines: ready for prime time? Nat Rev Genet 9: 776-788.
3. Sardesai, NY and Weiner, DB (2011). Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 23: 421-429.
4. Geall, AJ, Mandl, CW and Ulmer, JB (2013). RNA: The new revolution in nucleic acid vaccines. Seminars in Immunol 25: 152-159.
5. Geall, AJ, Verma, A, Otten, GR, Shaw, CA, Hekele, A, Banerjee, K et al. (2012). Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 109: 14604-14609.
6. Petsch, B, Schnee, M, Vogel, AB, Lange, E, Hoffmann, B, Voss, D et al. (2012). Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30: 1210-1216.
7. Luo, D and Saltzman, WM (2000). Synthetic DNA delivery systems. Nat Biotechnol 18: 33-37.
8. Perri, S, Greer, CE, Thudium, K, Doe, B, Legg, H, Liu, H et al. (2003). An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77: 10394-10403.
9. Rayner, JO, Dryga, SA and Kamrud, KI (2002). Alphavirus vectors and vaccination. Rev Med Virol 12: 279-296.
10. Barnett, SW, Burke, B, Sun, Y, Kan, E, Legg, H, Lian, Y et al. (2010). Antibodymediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 84: 5975-5985.
11. Bernstein, DI, Reap, EA, Katen, K, Watson, A, Smith, K, Norberg, P et al. (2009). Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28: 484-493.
12. Atkins, GJ, Fleeton, MN and Sheahan, BJ (2008). Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 10: e33.
13. Robert-Guroff, M (2007). Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 18: 546-556.
14. Smerdou, C and Liljestrm, P (1999). Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr Opin Mol Ther 1: 244-251.
15. Zimmer, G (2010). RNA replicons - a new approach for influenza virus immunoprophylaxis. Viruses 2: 413-434.
16. OHagan, DT, Ott, GS, Nest, GV, Rappuoli, R and Giudice, GD (2013). The history of MF59() adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 12: 13-30.
17. Swanson, KA, Settembre, EC, Shaw, CA, Dey, AK, Rappuoli, R, Mandl, CW et al. (2011). Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 108: 9619-9624.
18. Liu, MA (2011). DNA vaccines: an historical perspective and view to the future. Immunol Rev 239: 62-84.
19. Doria-Rose, NA, Learn, GH, Rodrigo, AG, Nickle, DC, Li, F, Mahalanabis, M et al. (2005). Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 79: 11214-11224.
20. Tritto, E, Mosca, F and De Gregorio, E (2009). Mechanism of action of licensed vaccine adjuvants. Vaccine 27: 3331-3334.
21. Seubert, A, Monaci, E, Pizza, M, OHagan, DT and Wack, A (2008). The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180: 5402-5412.
22. Calabro, S, Tortoli, M, Baudner, BC, Pacitto, A, Cortese, M, OHagan, DT et al. (2011). Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29: 1812-1823.
23. OHagan, DT, Ott, GS, De Gregorio, E and Seubert, A (2012). The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 30: 4341-4348.
24. Hippalgaonkar, K, Majumdar, S and Kansara, V (2010). Injectable lipid emulsionsadvancements, opportunities and challenges. AAPS PharmSciTech 11: 1526-1540.
25. Choi, WJ, Kim, JK, Choi, SH, Park, JS, Ahn, WS and Kim, CK (2004). Low toxicity of cationic lipid-based emulsion for gene transfer. Biomaterials 25: 5893-5903.
26. Ott, G, Singh, M, Kazzaz, J, Briones, M, Soenawan, E, Ugozzoli, M et al. (2002). A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J Controlled Release 79: 1-5.
27. Roman, VR, Jensen, KJ, Jensen, SS, Leo-Hansen, C, Jespersen, S, Te, DD et al. (2013). Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau. AIDS Res and Human Retroviruses 29: 1504-1512.
28. Spearman, P, Lally, MA, Elizaga, M, Montefiori, D, Tomaras, GD, McElrath, MJ et al. (2011). A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 203: 1165-1173.
29. Smith, LR, Wloch, MK, Ye, M, Reyes, LR, Boutsaboualoy, S, Dunne, CE et al. (2010). Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28: 2565-2572.
30. Lv, H, Zhang, S, Wang, B, Cui, S and Yan, J (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114: 100-109.
31. Xu, L and Anchordoquy, T (2011). Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acidbased therapeutics. J Pharmaceut Sci 100: 38-52.
32. Johansson, DX, Ljungberg, K, Kakoulidou, M and Liljestrm, P (2012). Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One 7: e29732.
33. Griffiths, PD, Stanton, A, McCarrell, E, Smith, C, Osman, M, Harber, M et al. (2011). Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377: 1256-1263.
34. Abel, K, Martinez, J, Yue, Y, Lacey, SF, Wang, Z, Strelow, L et al. (2011). Vaccineinduced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J Virol 85: 2878-2890.
35. Kormann, MS, Hasenpusch, G, Aneja, MK, Nica, G, Flemmer, AW, Herber-Jonat, S et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29: 154-157.
36. Wolff, JA, Malone, RW, Williams, P, Chong, W, Acsadi, G, Jani, A et al. (1990). Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
37. Pollard, C, Rejman, J, De Haes, W, Verrier, B, Van Gulck, E, Naessens, T et al. (2013). Type I IFN counteracts the induction of antigen-specific immune responses by lipidbased delivery of mRNA vaccines. Mol Ther 21: 251-259.
38. Fotin-Mleczek, M, Duchardt, KM, Lorenz, C, Pfeiffer, R, Ojkić-Zrna, S, Probst, J et al. (2011). Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34: 1-15.
39. Kallen, KJ, Heidenreich, R, Schnee, M, Petsch, B, Schlake, T, Thess, A et al. (2013). A novel, disruptive vaccination technology: Self-adjuvanted RNActive ((R)) vaccines. Human Vaccines & Immunotherapeutics 9: 2263-2276.
40. Scheel, B, Teufel, R, Probst, J, Carralot, JP, Geginat, J, Radsak, M et al. (2005). Toll-like receptor-dependent activation of several human blood cell types by protaminecondensed mRNA. Eur J Immunol 35: 1557-1566.
41. Weide, B, Pascolo, S, Scheel, B, Derhovanessian, E, Pflugfelder, A, Eigentler, TK et al. (2009). Direct injection of protamine-protected mRNA: results of a phase vaccination trial in metastatic melanoma patients. J Immunother 32: 498-507.
42. Hoerr, I, Obst, R, Rammensee, HG and Jung, G (2000). In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30: 1-7.
43. Mooij, P, Bogers, WM, Oostermeijer, H, Koornstra, W, Ten Haaft, PJ, Verstrepen, BE et al. (2000). Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J Virol 74: 4017-4027.
44. Montefiori, DC (2009). Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 485: 395-405.
45. Loomis, RJ, Lilja, AE, Monroe, J, Balabanis, KA, Brito, LA, Palladino, G et al. (2013). Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 31: 919-926.
46. Srivastava, IK, Stamatatos, L, Legg, H, Kan, E, Fong, A, Coates, SR et al. (2002). Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol 76: 2835-2847.